Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance
Open Access
- 12 November 2020
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (6), 1762-1766
- https://doi.org/10.3324/haematol.2020.263319
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesNature Medicine, 2020
- Clinical Applications of Chromosomal Microarray Testing in Myeloid MalignanciesCurrent Hematologic Malignancy Reports, 2020
- Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasmsCancer Genetics, 2018
- Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working groupCancer Genetics, 2018
- Clinical significance of somatic mutation in unexplained blood cytopeniaBlood, 2017
- Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significanceLaboratory Investigation, 2016
- Targeted sequencing identifies patients with preclinical MDS at high risk of disease progressionBlood, 2015
- MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significanceBlood, 2015
- Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignanciesBlood, 2011
- High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survivalBlood, 2008